GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » Common Stock

IGC Pharma (FRA:IGS1) Common Stock : €123.49 Mil (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is IGC Pharma Common Stock?

IGC Pharma's quarterly common stock declined from Jun. 2024 (€118.31 Mil) to Sep. 2024 (€115.85 Mil) but then increased from Sep. 2024 (€115.85 Mil) to Dec. 2024 (€123.49 Mil).

IGC Pharma's annual common stock increased from Mar. 2022 (€105.35 Mil) to Mar. 2023 (€111.11 Mil) and increased from Mar. 2023 (€111.11 Mil) to Mar. 2024 (€114.46 Mil).


IGC Pharma Common Stock Historical Data

The historical data trend for IGC Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Common Stock Chart

IGC Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 85.75 92.17 105.35 111.11 114.46

IGC Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 113.03 114.46 118.31 115.85 123.49

IGC Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


IGC Pharma Business Description

Traded in Other Exchanges
Address
10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

IGC Pharma Headlines

No Headlines